Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9377214 | 0.69 | ALDH1A1 (0.37) | HDAC1 | |
| SCHEMBL6386111 | 0.62 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL11226662 | 0.62 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL12298052 | 0.62 | — | — | |
| SCHEMBL16024979 | 0.58 | HTT (0.32) | — | |
| SCHEMBL1400082 | 0.58 | — | — | |
| SCHEMBL25954608 | 0.58 | ALDH1A1 (0.33) | — | |
| SCHEMBL12245280 | 0.57 | CCNE2 (0.33) | — | |
| SCHEMBL11244798 | 0.56 | KIF11 (0.34) | — | |
| SCHEMBL1884589 | 0.55 | ALDH1A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501846-B1 | TRICYCLIC MACROLIDE ANTIBACTERIAL COMPOUNDS | ABBOTT LAB (US) | 2009-03-18 | — | — | EP | disclosed |
| US-6992069-B2 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2006-01-31 | — | — | US | disclosed |
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | ABBVIE INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029818-A1 | Tricyclic macrolide antibacterial compounds | RPN1, CASP1, MRPL21 | HDAC1 23/4885MLYCD 1253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.